Skip to main content
. 2017 Nov 27;15:41–50. doi: 10.1016/j.redox.2017.11.022

Fig. 3.

Fig. 3

The levels of phospholipid and free fatty acids as well as the activities of PLA2, COX1 and COX2 in the kidney of hypertensive rats (A-SHR; B-DOCA-salt) and hypertensive rats after the administration of URB597. Data points represent the mean ± SD, n = 6; (a, significantly different from WKY group, p < 0.05; b, significantly different from SHR group, p < 0.05). B. Data points represent the mean ± SD; n = 6; (a, significantly different from Wistar group, p < 0.05); b, significantly different from DOCA-salt group, p < 0.05). The results are shown in comparison to the control groups [WKY rats and Wistar rats]: fatty acids level (PH AA: 10.68 ± 0.66 µmol/g tissue for WKY rats, 33.8 ± 1.5 µmol/g tissue for Wistar rats; PH DHA: 0.88 ± 0.05 µmol/g tissue for WKY rats, 2.74 ± 0.13 µmol/g tissue for Wistar rats; free AA: 479 ± 28 nmol/g tissue for WKY rats, 904 ± 47 nmol/g tissue for Wistar rats; free DHA: 51.5 ± 2.7 nmol/g tissue for WKY rats, 91. ± 4.9 nmol/g tissue for Wistar rats); cPLA2 activity (1.71 ± 0.08 nmol/min/mg prot. for WKY rats, 1.27 ± 0.06 nmol/min/mg prot. for Wistar rats); COX's activity (COX 1: 11.6 ± 0.7 nmol/min/mg prot. for WKY rats, 9.30 ± 0.41 nmol/min/mg prot. for Wistar rats; COX 2: 6.23 ± 0.31 nmol/min/mg prot. for WKY rats, 8.88 ± 0.44 nmol/min/mg prot. for Wistar rats).